Clinuvel Pharmaceuticals Limited

CUV

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).

CurveBeam AI Limited

CVB

CurveBeam AI Ltd. engages in the research, design, and manufacture of cone beam computed tomography imaging systems. The company is headquartered in Hatfield, Pennsylvania. The company went IPO on 2023-08-23. The firm is engaged in providing point-of-care diagnostic cone beam CT imaging solutions with artificial intelligence (AI) and deep learning AI (DLAI). Its product categories include orthopedics and bone health. Its orthopedics products include HiRise, LineUP, pedCAT Premium, pedCAT, InReach, and CubeVue Software. Its bone health products include InReach HR-pQCT, and OSSView. HiRise is a bilateral, weight bearing CT imaging of the entire lower extremities including hips/pelvis, distal upper extremities. LineUP is a bilateral, weight bearing CT imaging of the distal lower extremities and distal upper extremities. InReach HR-pQCT is a high resolution peripheral quantitative CT (HR-pQCT) imaging system designed for the point-of-care. OssView Bone Fragility software analyzes HR-pQCT images to measure the bone microarchitecture.

Count Limited

CUP

Count Ltd. is a holding company, which engages in providing accounting and financial services. The company is headquartered in Sydney, New South Wales. The company went IPO on 2010-12-22. The firm provides a range of services, including accounting, financial advice and financial services. The firm subsidiary, Twomeys Group Pty Ltd, is specialized in accounting, tax, bookkeeping and advisory services. The Company, through Diverger Limited, offers technical support, tax training, separately managed accounts (SMAs) and information technology (IT) services. The firm has three segments. Core Firms comprises the provision of accounting, audit and assurance, taxation, financial planning services and business and corporate advisory services. Financial Advice comprises of financial advice services provided by Australian Financial Services License (AFSL) holders. Core Related comprises of services that support the activities of the Core Firms.

Global X S&P Biotech ETF

CURE

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.